reports
EQS-News: Scherzer & Co. AG: Veröffentlichung Geschäftsbericht 2023
EQS-News: Scherzer & Co. AG / Schlagwort(e): Jahresbericht Scherzer & Co. AG: Veröffentlichung Geschäftsbericht 2023 24.04.2024 / 16:51 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Scherzer & Co. AG: Veröffentlichung Geschäftsbericht 2023 Die Scherzer & Co. AG hat heute den Geschäftsbericht 2023 veröffentlicht und im Bundesanzeiger zu ihrer am 03. Juni 2024 stattfindenden ordentlichen Hauptversammlung eingeladen. Der Bericht steht ab sofort unter zum Download zur Verfügung. Köln, 24. April 2024 Der VorstandÜber die Scherzer & Co. ...
Sino AG: 1 director
A director at Sino AG bought 516 shares at 36.716EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...
FFW Corporation Announces Earnings for the Quarter and Year to Date En...
FFW Corporation Announces Earnings for the Quarter and Year to Date Ended March 31, 2024 WABASH, Ind., April 24, 2024 (GLOBE NEWSWIRE) -- FFW Corporation (the “Corporation”) (OTC PINK: FFWC) (4/23/2024 Close: $34.65), parent corporation of Crossroads Bank (the “Bank”), announced earnings for the quarter and year to date ended March 31, 2024. For the three months ended March 31, 2024, the Corporation reported net income of $920,000 or $0.82 per common share compared to $1,216,000 or $1.07 per common share for the three months ended March 31, 2023. Net interest income for the three months ...
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with B...
ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4. METIS was a randomized phase 3 clinical trial of stereotactic radiosurgery with or without Tumor Treating Fields (TTFields) therapy for patients with 1-10 brain metastases from NSCLC. In March, METIS met its primary endpoint, demonstrating a statistically significant improvem...
EQS-News: MorphoSys präsentiert neue Daten der Phase 3 MANIFEST-2 Stud...
EQS-News: MorphoSys AG / Schlagwort(e): Konferenz MorphoSys präsentiert neue Daten der Phase 3 MANIFEST-2 Studie zu Pelabresib bei Myelofibrose in mündlichem Vortrag auf der ASCO-Jahrestagung 2024 24.04.2024 / 16:40 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Pressemitteilung Planegg/München, Deutschland, 24. April 2024 MorphoSys präsentiert neue Daten der Phase 3 MANIFEST-2 Studie zu Pelabresib bei Myelofibrose in mündlichem Vortrag auf der ASCO-Jahrestagung 2024 Weitere Posterpräsentation im Rahmen von ASCO 2024 zeigt neue Er...
EQS-News: MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabres...
EQS-News: MorphoSys AG / Key word(s): Conference MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting 24.04.2024 / 16:40 CET/CEST The issuer is solely responsible for the content of this announcement. Media Release Planegg/Munich, Germany, April 24, 2024 MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat Morpho...
Schweiter Technologies Ag: 1 director
A director at Schweiter Technologies Ag bought 150 shares at 412.748CHF and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
- ABGSC Construct. & Real Estate Research
- Fredrik Stensved
- Markus Henriksson
- Viktor Stenlöf
Invitation til præsentation af ALK’s regnskab for første kvartal freda...
Invitation til præsentation af ALK’s regnskab for første kvartal fredag den 3. maj 2024 ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør delårsrapport for de første tre måneder af 2024 (Q1) om morgenen fredag den 3. maj 2024. ALK afholder senere samme dag kl. 12.30 (CET) en præsentation for investorer og analytikere, hvor ledelsen kommenterer på resultat og forventninger samt besvarer spørgsmål. ALK vil være repræsenteret ved Peter Halling, Adm. direktør, Claus Steensen Sølje, Finansdirektør og Per Plotnikof, IR chef. Live audio webcast Mødet audiocastes live på , hvor genafspiln...
Invitation to the presentation of ALK’s first quarter results on Frida...
Invitation to the presentation of ALK’s first quarter results on Friday 3 May 2024 ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its first quarter results in the morning of 3 May 2024. Later same day, the company will host a presentation for investors and analysts at 12:30 CET, where ALK’s management will comment on the first quarter results and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast The meeting will be audio webcasted live and be availabl...
Xtract One Closes $7.2M Public Offering and $1.4M Investment by Strate...
Xtract One Closes $7.2M Public Offering and $1.4M Investment by Strategic Partner THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, April 24, 2024 (GLOBE NEWSWIRE) -- Xtract One Technologies Inc. (TSX: XTRA) (OTCQX: XTRAF) (FRA: 0PL) (“Xtract One” or the “Company”) announces that it has closed its previously announced public offering (the “Offering”) conducted by Eight Capital, as lead agent and sole bookrunner, and Echelon Wealth Partners Inc. (together wit...
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary F...
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University’s Lombardi Comprehensive Cancer Center NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transforma...
EQS-News: Cherry SE: Neubewertung von Vermögensgegenständen
EQS-News: Cherry SE / Schlagwort(e): Sonstiges Cherry SE: Neubewertung von Vermögensgegenständen 24.04.2024 / 16:23 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. München, 24. April 2024 – Cherry SE korrigiert alte Annahmen zur Unternehmensentwicklung und nimmt konservative, nicht zahlungswirksame Neubewertungen vor Die Cherry SE nimmt bilanzielle Wertberichtigungen von Vermögensgegenständen im Jahresabschluss 2023 vor. Diese nicht-zahlungswirksamen Abschreibungen betreffen immaterielle Vermögenswerte, im Wesentlichen den Goodwill, ...
EQS-News: Cherry SE: Revaluation of assets
EQS-News: Cherry SE / Key word(s): Miscellaneous Cherry SE: Revaluation of assets 24.04.2024 / 16:23 CET/CEST The issuer is solely responsible for the content of this announcement. Munich, 24. April 2024 - Cherry SE corrects old assumptions about the company's development and carries out conservative, non cash-effective revaluations Cherry SE is recognizing asst impairments in the 2023 annual financial statements. These non-cash items relate to intangible assets, mainly goodwill, as well as property, plant and equipment and amount to approximately EUR 96 million. Accordi...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of CITGO Holding, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 18 April 2024 in which Moody's reassessed the appropriateness of the ratings in the con...
Ensari Deri Gida Sanayi Ve Ticaret A S: 1 director
A director at Ensari Deri Gida Sanayi Ve Ticaret A S sold 4,425,000 shares at 25.340TRY and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over ...
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- Olof Cederholm
Fly Play hf.: Increase of share capital
Fly Play hf.: Increase of share capital Reference is made to the announcement of Fly Play hf. (“PLAY” or the “Company”) on April 11, 2024, regarding the results of a funding round. In a meeting held today, the Company’s Board of Directors decided to exercise the authority granted by the AGM to increase the Company’s share capital by issuing new shares by up to 1,200,000,000 shares in nominal value. As previously announced, the total amount of the authorization will not be used. The Company's Board of Directors decided at a meeting today to increase the Company's share capital by issuing 1...
Ultimovacs Announces Poster Presentation at the 2024 American Society ...
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. INITIUM is an Ultimovacs-sponsored randomized, comparative, multi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.